Nature Communications

REACtiVe-2: phase I evaluation of dendritic cell vaccination and agonistic CD40 therapy following (m)FOLFIRINOX in metastatic pancreatic cancer

2025-11-28

Full text

DOI https://doi.org/10.1038/s41467-025-66092-1